ct-1.3

CT1-3 is a potent anti-cancer agent. CT1-3 regulates the JNK/Bcl-2/Bax/XIAP pathway, which induces mitochondria-mediated apoptosis. CT1-3 regulates the E-cadherin/Snail axis to inhibit epithelial mesenchymal transition (EMT) potentials in human cancer cells (HCCs) and suppresses tumourigenesis. CT1-3 has anti-tumour effects in mouse models and does not show significant hepatotoxicity or nephrotoxicity.

Aprocitentan-D4 is a deuterium-labeled Aprocitentan. Aprocitentan (T7817) is a major and pharmacologically active metabolite of Macitentan. Aprocitentan (T7817) is a dual ETA/ETB antagonist (IC50s: 3.4 nM and 987 nM; pA2s: 6.7 and 5.5).

Netropsin is a basic polypeptide isolated from Streptomyces netropsis with antibiotic and antiviral activity. It is strong, specific binding to A-T areas of DNA is useful to genetics research. Netropsin is active against Gram-negative bacteria and Gram-po

CT-133 is a selective and potent antagonist of the CRTH2 Receptor, with a Ki value of 2.2 nM, and exhibits a Ki greater than 3800 nM for the DP1 receptor. It inhibits PGD2-induced neutrophil migration and significantly reduces lung inflammation and improves lung function impairment in a mouse model of acute lung injury (ALI) induced by cigarette smoke. Additionally, CT-133 effectively suppresses the overexpression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and the chemokine (KC) while reversing the suppression of the anti-inflammatory factor IL-10. CT-133 is useful for ALI research.

CCT 137690 is a highly specific and oral-available aurora kinase inhibitor, for aurora A(IC50=15 nM ), B(IC50=25 nM) and C(IC50=19 nM).

Aprocitentan (ACT-132577) is ETA and ETB antagonist .